Author: Pannirselvam, Malar ; Yim, Samantha ; Carabajal, Esteban ; Kowalski, Beatriz ; Peat, Andrew J. ; Lo, Gary ; Sweeney, David ; Zhou, Jiayi ; McAllaster, Michael ; Terrell, Ashley ; Mueller, Elizabeth A. ; Chen, Yi-Pei ; Jeyasingh, Sam ; Dalmas Wilk, Deidre ; Lehmann, Stephanie ; Momont, Corey ; Newby, Zachary ; Colas, Christophe ; Pearson, Neil ; Eberl, H. Christian ; Ranjan, Rohit ; Grosse, Johannes ; Cato, Matthew ; Gordon, Earl ; Fernandez, Beth ; Wang, Shuya ; Telenti, Amalio ; Hetzler, Belinda ; Safabakhsh, Pegah ; Cai, Haiying ; Cassidy, James ; Chen, Dingjun ; McHugh, Charles ; Tse, Winston ; Plastridge, Bob ; Wang, Lisha ; Bohan, Dana ; Soriaga, Leah ; Oladunni, Fatai ; Nigro, Maria ; Adolph, Ramona S. ; Talecki, Lindsey ; Bantscheff, Marcus ; Wedel, Laura ; Park, Arnold ; Darwech, Isra ; Stokes, Neil ; Bagchi, Parikshit ; Adams, Ashley M. ; Werner, Thilo ; Bartha, Istvan ; Chaudhary, Khuram W. ; Balce, Dale ; Hansen, Justin ; Pero, Joseph E. ; Barauskas, Ona ; Hwang, Seungmin ; Shapiro, Nathan D.

In the aftermath of the COVID-19 pandemic, opportunities to modulate biological pathways common to the lifecycles of viruses need to be carefully considered. N-linked glycosylation in humans is mediated exclusively by the oligosaccharyltransferase complex and is frequently hijacked by viruses to facilitate infection. As such, STT3A/B, the catalytic domain of the OST complex, became an intriguing drug target with broad-spectrum antiviral potential. However, due to the critical role N-linked glycosylation plays in a number of fundamental human processes, the toxicological ramifications of STT3A/B inhibition required attention commensurate to that given to antiviral efficacy. Herein, we describe how known STT3A/B inhibitor NGI-1 inspired the discovery of superior tool compounds which were evaluated in in vitro efficacy and translational safety (e.g., CNS, cardiovascular, liver) studies. The described learnings will appeal to those interested in the therapeutic utility of modulating N-linked glycosylation as well as the broader scientific community.

01 Jan 2020·British Journal of PharmacologyQ2 · MEDICINE

Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet‐induced metabolic dysfunction and non‐alcoholic fatty liver disease in mice

Q2 · MEDICINE

Article

Author: Lee, Jinq‐Chyi ; Huang, Hsiu‐Chen ; Huang, Hsing ; Chiang, Hao ; Liu, Hui‐Kang ; Huang, Cheng

Background and PurposeNon‐alcoholic fatty liver disease (NAFLD), including non‐alcoholic steatohepatitis, is closely related to metabolic diseases such as obesity and diabetes. Despite an accumulating number of studies, no pharmacotherapy that targets NAFLD has received general approval for clinical use.Experimental ApproachInhibition of the sodium‐glucose cotransporter 2 (SGLT2) is a promising approach to treat diabetes, obesity, and associated metabolic disorders. In this study, we investigated the effect of a novel SGLT2 inhibitor, NGI001, on NAFLD and obesity‐associated metabolic symptoms in high‐fat diet (HFD)‐induced obese mice.Key ResultsDelayed intervention with NGI001 protected against body weight gain, hyperglycaemia, hyperlipidaemia, and hyperinsulinaemia, compared with HFD alone. Adipocyte hypertrophy was prevented by administering NGI001. NGI001 inhibited impaired glucose metabolism and regulated the secretion of adipokines associated with insulin resistance. In addition, NGI001 supplementation suppressed hepatic lipid accumulation and inflammation but had little effect on kidney function. In‐depth investigations showed that NGI001 ameliorated fat deposition and increased AMPK phosphorylation, resulting in phosphorylation of its major downstream target, acetyl‐CoA carboxylase, in human hepatocyte HuS‐E/2 cells. This cascade ultimately led to the down‐regulation of downstream fatty acid synthesis‐related molecules and the up‐regulation of downstream β oxidation‐associated molecules. Surprisingly, NGI001 decreased gene and protein expression of SGLT1 and SGLT2 and glucose uptake in oleic acid‐treated HuS‐E/2 cells.Conclusion and ImplicationsOur findings suggest the novel SGLT2 inhibitor, NGI001 has therapeutic potential to attenuate or delay the onset of diet‐induced metabolic diseases and NAFLD.

15 Jan 2019·Clinical Cancer ResearchQ1 · MEDICINE

No Sugar Added: A New Strategy to Inhibit Glioblastoma Receptor Tyrosine Kinases

Q1 · MEDICINE

Article

Author: Wahl, Daniel R. ; Lawrence, Theodore S.

AbstractA novel inhibitor of N-linked glycosylation (NGI-1) inhibits the glycosylation and phosphorylation of multiple receptor tyrosine kinases in glioblastoma (GBM). NGI-1 sensitizes multiple models of GBM to chemotherapy and radiation in vitro and in vivo and may be especially effective in GBMs that retain active PTEN.See related article by Baro et al., p. 784

100 Deals associated with NGI001

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	Preclinical	CN	National Yang Ming University	12 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NGI001

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation